Amneal highlighted the benefits of a broad spread of generics and an increased shift towards complex products with high barriers to entry, as it reported generics sales growth in Q1 despite a tough operating environment for US generics.
Amneal says that a lack of over-reliance on just a few key generics in its portfolio, as well as an overall shift towards focusing on more complex generics with higher barriers to entry, have helped the firm to weather the current pressures of the US generics market in the first quarter of 2022.
First-quarter generics sales were up 2% to $318m, albeit with reported operating income for the segment falling by a third to $45.3m
Thanks to its efficient development pipeline, sales of Amgen’s biosimilars neared $750m for the first three months of the year, offering some comfort as the firm gears up for the loss of exclusivity for its denosumab franchise.
During Organon’s first-quarter results call, CEO Kevin Ali discussed the exposure of the biosimilars business to US tariffs, as well as pointing to the recent acquisition of Tofidence (tocilizumab-bavi) from Biogen as an opportunity for growth, as the segment saw a double-digit decline.
Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”
Generics Bulletin previews the most noteworthy and anticipated events for May 2025.
